BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai C, Wang Y, Chen K, Chen C, Wang C. The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Viruses 2022;14:1706. [DOI: 10.3390/v14081706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lai CC, Hsueh PR. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. J Med Virol 2022;95. [PMID: 36571273 DOI: 10.1002/jmv.28430] [Reference Citation Analysis]
2 Naidoo DB, Chuturgoon AA. The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. Mol Diagn Ther 2023;:1-34. [PMID: 36656511 DOI: 10.1007/s40291-022-00634-x] [Reference Citation Analysis]
3 Bellino S. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients. Ann Med 2022;54:2856-60. [PMID: 36259490 DOI: 10.1080/07853890.2022.2133162] [Reference Citation Analysis]
4 Weng TC, Weng TS, Lai CC, Chao CM, Wang JH. Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2022;20:1615-22. [PMID: 36317748 DOI: 10.1080/14787210.2022.2142117] [Reference Citation Analysis]
5 Poznański P, Augustyniak-Bartosik H, Magiera-Żak A, Skalec K, Jakuszko K, Mazanowska O, Janczak D, Krajewska M, Kamińska D. Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients. Viruses 2022;14:2224. [PMID: 36298779 DOI: 10.3390/v14102224] [Reference Citation Analysis]